ZyVersa Therapeutics Stock (NASDAQ:ZVSA)
Previous Close
$1.24
52W Range
$1.04 - $42.35
50D Avg
$2.08
200D Avg
$4.54
Market Cap
$1.32M
Avg Vol (3M)
$1.22M
Beta
0.64
Div Yield
-
ZVSA Company Profile
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.